Meagan O'brien

Title: Meagan O’Brien: Patent Work in Allergy Research.

Introduction

Meagan O’Brien is an inventor based in Tarrytown, New York, and is associated with Regeneron Pharmaceuticals, Inc. Her patent work concerns gene-expression methods for evaluating cat allergy and potential antibody-based approaches to asthma exacerbations triggered by cat allergens.

Latest Patents

O’Brien is named on one patent, Methods of Identifying and Evaluating Cat Allergy Gene Signatures in a Subject by Determining a Stratified Score Based on Gene Expression. The disclosure describes methods for identifying subjects who may be suitable for treatment or prevention of cat-allergen-induced asthma exacerbations using antibodies. It also describes administering at least one antibody to treat or help prevent such exacerbations. The supplied information lists 1 patent for O’Brien.

Career Highlights

O’Brien’s listed patent reflects research at the intersection of gene-expression analysis, allergy, and therapeutic antibody development. Her work is associated with Regeneron Pharmaceuticals, Inc., a company engaged in biopharmaceutical research and development.

Collaborations

Wei Keat Lim and Jennifer D. Hamilton are identified as O’Brien’s coworkers. Their names are provided as professional associations, though the supplied information does not specify their roles in the patent.

Conclusion

Meagan O’Brien’s patent contribution focuses on evaluating cat allergy gene signatures and exploring antibody-based strategies for cat-allergen-induced asthma exacerbations.